{
    "organizations": [],
    "uuid": "454fba83d9371c6867d8b6d15a0ee90d7ed7a22b",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/13/globe-newswire-adamas-to-announce-fourth-quarter-and-full-year-2017-financial-results-and-host-conference-call-on-february-22-2018.html",
    "ord_in_thread": 0,
    "title": "Adamas to Announce Fourth and Full Year 2017 Financial Results and Host Conference Call on February 22, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "EMERYVILLE, Calif., Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report fourth quarter and full year 2017 financial results on Thursday, February 22, 2018 after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.\nInvestor Conference Call and Webcast\nThe conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at http://ir.adamaspharma.com/events.cfm and will be available for replay until March 22, 2018.\nAbout Adamas Pharmaceuticals, Inc.\nAdamas is using its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases. The company is building upon the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease, with a pipeline of differentiated investigational programs, which includes ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified-release lacosamide in development for the treatment of partial-onset seizures in patients with epilepsy. Adamas’ goal is to create and commercialize a new generation of neurological medicines intended to lessen the burden of disease on patients, caregivers and society. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com .\nContact:\nMedia:\nKim Kraemer\n415-939-9033\nkkraemer@waterhousebrands.com\nInvestors:\nAshleigh Barreto\nDirector, Corporate Communications & Investor Relations\nAdamas Pharmaceuticals, Inc.\n510-450-3567\nir@adamaspharma.com\nSource:Adamas Pharmaceuticals, Inc.",
    "published": "2018-02-14T00:01:00.000+02:00",
    "crawled": "2018-02-14T02:02:19.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "emeryville",
        "adamas",
        "pharmaceutical",
        "nasdaq",
        "adms",
        "today",
        "announced",
        "company",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "thursday",
        "february",
        "market",
        "close",
        "subsequently",
        "adamas",
        "management",
        "team",
        "host",
        "conference",
        "call",
        "webcast",
        "eastern",
        "time",
        "discus",
        "financial",
        "result",
        "provide",
        "corporate",
        "update",
        "investor",
        "conference",
        "call",
        "webcast",
        "conference",
        "call",
        "accessed",
        "dialing",
        "participant",
        "canada",
        "international",
        "caller",
        "webcast",
        "accessed",
        "live",
        "via",
        "investor",
        "section",
        "adamas",
        "website",
        "http",
        "available",
        "replay",
        "march",
        "adamas",
        "pharmaceutical",
        "adamas",
        "using",
        "deep",
        "understanding",
        "biology",
        "redefine",
        "treatment",
        "experience",
        "patient",
        "suffering",
        "chronic",
        "neurological",
        "disease",
        "company",
        "building",
        "upon",
        "commercial",
        "launch",
        "amantadine",
        "extended",
        "release",
        "capsule",
        "previously",
        "first",
        "medicine",
        "treatment",
        "dyskinesia",
        "patient",
        "parkinson",
        "disease",
        "pipeline",
        "differentiated",
        "investigational",
        "program",
        "includes",
        "development",
        "treatment",
        "multiple",
        "sclerosis",
        "walking",
        "impairment",
        "lacosamide",
        "development",
        "treatment",
        "seizure",
        "patient",
        "epilepsy",
        "adamas",
        "goal",
        "create",
        "commercialize",
        "new",
        "generation",
        "neurological",
        "medicine",
        "intended",
        "lessen",
        "burden",
        "disease",
        "patient",
        "caregiver",
        "society",
        "information",
        "adamas",
        "unique",
        "approach",
        "developing",
        "medicine",
        "based",
        "biology",
        "please",
        "visit",
        "contact",
        "medium",
        "kim",
        "kraemer",
        "kkraemer",
        "investor",
        "ashleigh",
        "barreto",
        "director",
        "corporate",
        "communication",
        "investor",
        "relation",
        "adamas",
        "pharmaceutical",
        "ir",
        "source",
        "adamas",
        "pharmaceutical",
        "inc"
    ]
}